| 1983 | The Binding Site Ltd was founded and launched with a range of highly specific polyclonal antisera used by clinical researchers worldwide. |
| 1987 | IgG Subclass RID kits first launched for the investigation of immunodeficiency. |
| 1988 | The Binding Site Inc in San Diego, USA was founded, the product range and customer base for clinical research antibodies continued to grow. |
| 1990 | First FDA cleared commercially available human IgG subclass kits for routine automated clinical use launched. |
| 1992 | Received Queen's Award for Export Achievement. |
| 1993 | The Binding Site GmbH in Heidelberg, Germany founded. Dominance achieved worldwide of the human IgG subclass testing market. |
| 1996 | The Binding Site France founded in Grenoble. |
| 2001 | The Binding Site Inc sign deal with Dynex technologies for distribution of their DSX fully automated EIA processor. |
| 2001 | First publication highlighting the clinical significance of Freelite in nonsecretory multiple myeloma patients is published in Blood. |
| 2003 | Publication highlighting the clinical utility of Freelite for the replacement of Bence Jones protein in The Lancet. |
| 2004 | First National guidelines for the incorporation of Freelite assays into the management of Primary Amyloidosis patients published in the British Journal of Haematology. |
| 2005 | International Consensus on Freelite assays for AL amyloidosis published in American Journal of Hematology. |
| 2005 | First direct sales into Canada by The Binding Site Inc. |
| 2006 | Freelite incorporated into the National UK guidelines for the diagnosis and monitoring of Multiple Myeloma published in the British Journal of Haematology. |
| 2006 | Freelite incorporated into new International uniform response criteria for multiple myeloma published in Leukemia. |
| 2006 | Mayo Clinic publish the first independent study in the USA recommending Freelite as a routine screening test in Mayo Clinic Proceedings. |
| 2007 | Number of DSX processors placed by The Binding Site in the USA reaches 150. |
| 2007 | The Binding Site Spain founded in Barcelona. |
| 2007 | Won Queen's Award for Enterprise in the category Innovation, for the Freelite serum free light chain assay. |
| 2007 | Journal of the American Society of Nephrology publishes the first study using Haemodialysis for the removal of serum free light chains as measured by Freelite. |
| 2007 | Clinical utility of Freelite for prognosis of multiple myeloma published in Blood and British Journal of Haematology. |
| 2007 | First Binding Site SPAPLUS automated analyser placed in US Cancer Centre to run Freelite assays. |
| 2008 | Launch of EuLite clinical trial using velcade-based chemotherapy and haemodialysis for the removal of serum free light chains as measured by Freelite. |
| 2008 | International Myeloma Working Group publish recommendations for use of Freelite in screening, prognosis and treatment response in Leukemia. |
| 2009 | Sale of Autoimmune business to Werfen Group |
| 2009 | Launch of Hevylite for analysis of immunoglobulin heavy chain/light chain (HLC) pairs |
| 2010 | The Binding Site s.r.o., for Czech Republic and Slovak Republic, founded in Prague, Czech Republic. |
| 2010 | New Binding Site office founded in Antwerp, Belgium to support customers in Belgium, Netherlands and Luxembourg. |
| 2010 | Won Queen's Award for Enterprise in the category International Trade. |
.jpg)